Steven Cohen's REGN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 201,499 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $113.3 M, representing 0.19% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2017, adding 411,354 shares. Largest reduction occurred in Q2 2020, reducing 387,331 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +14,501 | Add 0.00% | 14,500 | $282.48 |
| Q3 2014 | +9,100 | Add 62.76% | 23,600 | $360.51 |
| Q4 2014 | -23,600 | Sold Out | 23,600 | $0.00 |
| Q1 2016 | +109,700 | New Buy | 109,700 | $360.44 |
| Q2 2016 | -109,700 | Sold Out | 109,700 | $0.00 |
| Q1 2017 | +70,000 | New Buy | 70,000 | $387.51 |
| Q2 2017 | -70,000 | Sold Out | 70,000 | $0.00 |
| Q4 2017 | +481,354 | New Buy | 481,354 | $375.96 |
| Q1 2018 | -282,254 | Reduce 58.64% | 199,100 | $344.36 |
| Q2 2018 | -171,400 | Reduce 86.09% | 27,700 | $344.98 |
| Q3 2018 | -27,700 | Sold Out | 27,700 | $0.00 |
| Q4 2018 | +168,644 | New Buy | 168,644 | $373.50 |
| Q1 2019 | -168,644 | Sold Out | 168,644 | $0.00 |
| Q2 2019 | +483,845 | New Buy | 483,845 | $313.00 |
| Q3 2019 | -42,905 | Reduce 8.87% | 440,940 | $277.40 |
| Q4 2019 | -440,940 | Sold Out | 440,940 | $0.00 |
| Q2 2020 | +53,609 | New Buy | 53,609 | $623.65 |
| Q3 2020 | -53,609 | Sold Out | 53,609 | $0.00 |
| Q2 2021 | +188,700 | New Buy | 188,700 | $558.54 |
| Q3 2021 | -188,700 | Sold Out | 188,700 | $0.00 |
| Q3 2023 | +1,407 | New Buy | 1,407 | $822.96 |
| Q4 2023 | -1,407 | Sold Out | 1,407 | $0.00 |
| Q2 2024 | +22,871 | New Buy | 22,871 | $1051.01 |
| Q3 2024 | -22,871 | Sold Out | 22,871 | $0.00 |
| Q2 2025 | +143,108 | New Buy | 143,108 | $525.00 |
| Q3 2025 | +58,391 | Add 40.80% | 201,499 | $562.27 |
Steven Cohen's Regeneron Pharmaceuticals Investment FAQs
Steven Cohen first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2014, acquiring 14,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Regeneron Pharmaceuticals, Inc. (REGN) for 46 quarters since Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q2 2019, adding 483,845 shares worth $151.44 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 201,499 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $113.3 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.19% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 483,845 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.